1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
662B02D7CE555C50E00258B6C004A1E6F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-more-effective-medical-affairs-product-launch-teams-immunology-segment
18
19
203.238.82.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Building More Effective Medical Affairs Product Launch Teams: Immunology Segment

ID: POP-388


Features:

12 Info Graphics

32 Data Graphics

660+ Metrics

19 Narratives


Pages: 56


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
In the dynamic field of immunology, Medical Affairs teams are central to orchestrating successful product launches, navigating the complex interplay between complex disease states, innovative treatments and patient needs. In many ways, Medical Affairs groups have become a key differentiator in this high-growth and highly competitive therapeutic space.

Best Practices, LLC undertook this benchmarking research to investigate the role of Medical Affairs in immunology product launches. The report investigates their evolving responsibilities, cross-functional alignment, effective activities, performance measurement, strategic resourcing, and digital utilization within the immunology therapeutic area. The report also identifies the key factors for success and the unique challenges that must be overcome for effective launch preparedness.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Academic; Research; Biotech; Chemical; Consulting; Consumer Products; Health Care; Medical Device; Science


Companies Profiled:
AstraZeneca; ASC Therapeutics; Boehringer Ingelheim; Duke University and Health System; EMD Serono; Genentech; GlaxoSmithKline ; Grünenthal; Helsinn; MEDiSTRAVA; Novartis; Pfizer; Pixacore; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies; Thermo Fisher Scientific

Study Snapshot

Best Practices, LLC engaged 23 Medical leaders from 16 leading life sciences companies in this benchmarking research study. Medical Directors and upper management executives represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study.

Key topics covered in this report include:

  • Medical Leadership Roles and Launch Activity Effectiveness in Immunology
  • Ensuring Cross-functional Alignment and Collaboration in Immunology Launches
  • Medical Launch Evolution in Immunology Segment
  • Immunology Launch Activities Timeline, Performance Tracking, and Resourcing
  • Critical Success Factors and Major Pitfalls for Medical Affairs During Immunology Launches
  • Digital Launch Implementation and Impact in Immunology
  • Launch Tool Deployment for Immunology Products

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Launch Tool Deployment: Immunology benchmark participants typically kick off digital activities one phase later than when they should ideally start, according to their own standards. The widest gap occurs in actual Medical Regulatory engagement time vs. ideal.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 4
II.
Section I: Launch Excellence and Medical’s Role & Activity EffectivenessPg. 6-12
III.
Section II: Ensuring Cross-functional Alignment and CollaborationPg. 13-15
IV.
Section III: Adopting to Ongoing Changes in Medical LandscapePg. 16-20
V.
Section IV: Launch Timeline, Preparedness Metrics, and ResourcingPg. 21-26
VI.
Section V: Critical Success Factors and Major PitfallsPg. 27-32
VII.
Section VI: Digital Influence on Launch Processes and Launch Tool DeploymentPg. 33-41
VIII.
Section VII: Participant DemographicsPg. 42-43
IX.
Section VIII: Detailed Benchmark Study DataPg. 44-55
X.
Section IX: About Best Practices, LLCPg. 56

    List of Charts & Exhibits

    I. Launch Excellence and Medical’s Role & Activity Effectiveness

    • Medical launch excellence framework
    • Medical Affairs’ role in immunology launches
    • Medical leadership roles in immunology launches
    • Medical Affairs’ effectiveness in immunology launch activities
    • Most effective launch activities for Medical Affairs in immunology
    • Improvement opportunities for Medical Affairs around immunology launch activities

    II. Ensuring Cross-functional Alignment and Collaboration

    • Medical Affairs’ work with internal colleagues to ensure successful immunology launches
    • Role of Medical Affairs group in cross-functional immunology launch teams

    III. Adopting to Ongoing Changes in Medical Landscape

    • Change fronts for Medical launch evolution
    • Medical Affairs’ launch evolution around digital data dissemination and communication
    • Medical Affairs’ launch evolution around medical education
    • Medical Affairs’ launch evolution around organizational support

    IV. Launch Timeline, Preparedness Metrics and Resourcing

    • Medical Affairs’ immunology launch activities timeline
    • Total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for immunology products during each of the years in launch phase
    • Launch dashboard and information used with the dashboard for immunology
    • Percentage of total Medical Affairs launch investment allocated to each of the listed Medical Affairs activities in immunology
    • Percentage of total Medical Affairs launch FTEs allocated to each of the listed Medical Affairs activities in immunology

    V. Critical Success Factors and Major Pitfalls

    • Critical success factors for Medical Affairs in immunology launches
    • Areas where advanced team planning is key for immunology launches
    • Six priority areas for successful Medical Affairs launch readiness in immunology
    • Major pitfalls for Medical Affairs during immunology launches
    • Six major challenge areas for Medical Affairs during immunology launches

    VI. Digital Influence on Launch Processes and Launch Tool Deployment

    • Post-pandemic digital technology utilization in Medical Affairs during immunology product launches
    • Impact of digital technologies on current and future immunology launch processes
    • Digital launch tool deployment and impact
    • Impact of top three digital activities that Medical leads in immunology
    • Impact of digital activities and programs used to support a successful immunology product launch
    • Top digital tools that can bring success to Medical Affairs product launch activities
    • Fast-growing digital tools that are impacting Medicals’ launch strategy
    • Example of a valuable digital tool that supports launch activities

    VII. Participant Demographics

    • Geographic responsibility of benchmark partners

    VIII. Detailed Benchmark Study Data

    • Role served by Medical Affairs in immunology product launches
    • Medical Affairs’ launch role effectiveness in immunology
    • Role served by Medical Affairs in planning, research, and education activities in immunology segment
    • Role served by Medical Affairs in data dissemination and organizational support activities in immunology segment
    • Role served by Medical Affairs in research activities in immunology segment
    • Role served by Medical Affairs in education and data dissemination support activities in immunology segment
    • Role served by Medical Affairs in organizational support activities in immunology segment
    • Medical Affairs launch activity involvement timeline - Evidence generation and field-based medical activities in immunology
    • Medical Affairs launch activity involvement timeline - Medical information and medical regulatory activities in immunology
    • Medical Affairs launch activity involvement timeline - HEOR activities and medical / scientific communications in immunology
    • Medical Affairs launch activity involvement timeline - Independent medical education and external engagement activities in immunology